Class information for: |
Basic class information |
ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
---|---|---|---|
5106 | 1603 | 50.9 | 91% |
Classes in level above (level 2) |
Terms with highest relevance score |
Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|---|
1 | RAF | Author keyword | 16 | 19% | 5% | 79 |
2 | RAF 1 | Author keyword | 14 | 22% | 3% | 56 |
3 | LEO JENKINS CANC | Address | 11 | 29% | 2% | 32 |
4 | C RAF 1 | Author keyword | 7 | 50% | 1% | 10 |
5 | A RAF | Author keyword | 7 | 57% | 0% | 8 |
6 | MAP KINASE KINASE | Author keyword | 7 | 34% | 1% | 16 |
7 | MED STRAHLENKUNDE ZELLFOR | Address | 6 | 20% | 2% | 26 |
8 | MAP KINASE ACTIVATOR | Author keyword | 6 | 100% | 0% | 4 |
9 | MICROTUBULE ASSOCIATED PROTEIN 2 KINASE | Author keyword | 6 | 100% | 0% | 4 |
10 | MED MED CLIN IMMUNOL ALLERGY | Address | 4 | 67% | 0% | 4 |
Web of Science journal categories |
Author Key Words |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | RAF | 16 | 19% | 5% | 79 | Search RAF | Search RAF |
2 | RAF 1 | 14 | 22% | 3% | 56 | Search RAF+1 | Search RAF+1 |
3 | C RAF 1 | 7 | 50% | 1% | 10 | Search C+RAF+1 | Search C+RAF+1 |
4 | A RAF | 7 | 57% | 0% | 8 | Search A+RAF | Search A+RAF |
5 | MAP KINASE KINASE | 7 | 34% | 1% | 16 | Search MAP+KINASE+KINASE | Search MAP+KINASE+KINASE |
6 | MAP KINASE ACTIVATOR | 6 | 100% | 0% | 4 | Search MAP+KINASE+ACTIVATOR | Search MAP+KINASE+ACTIVATOR |
7 | MICROTUBULE ASSOCIATED PROTEIN 2 KINASE | 6 | 100% | 0% | 4 | Search MICROTUBULE+ASSOCIATED+PROTEIN+2+KINASE | Search MICROTUBULE+ASSOCIATED+PROTEIN+2+KINASE |
8 | RAF 1 KINASE | 3 | 24% | 1% | 9 | Search RAF+1+KINASE | Search RAF+1+KINASE |
9 | ARAF | 2 | 67% | 0% | 2 | Search ARAF | Search ARAF |
10 | EXTRACELLULAR SIGNAL REGULATED KINASE 2 ERK2 | 2 | 67% | 0% | 2 | Search EXTRACELLULAR+SIGNAL+REGULATED+KINASE+2+ERK2 | Search EXTRACELLULAR+SIGNAL+REGULATED+KINASE+2+ERK2 |
Key Words Plus |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | STIMULATED PROTEIN | 44 | 76% | 2% | 31 |
2 | V RAF | 41 | 52% | 3% | 56 |
3 | A RAF | 41 | 54% | 3% | 53 |
4 | ONCOGENIC P21RAS | 34 | 93% | 1% | 13 |
5 | ERKS | 23 | 65% | 1% | 22 |
6 | DIFFERENTIAL ABILITIES | 21 | 71% | 1% | 17 |
7 | C RAF | 17 | 34% | 3% | 41 |
8 | C RAF 1 | 14 | 43% | 2% | 26 |
9 | ABROGATE CYTOKINE DEPENDENCY | 14 | 55% | 1% | 18 |
10 | TYROSINE THREONINE KINASE | 14 | 53% | 1% | 18 |
Journals |
Reviews |
Title | Publ. year | Cit. | Active references | % act. ref. to same field |
---|---|---|---|---|
PROTEIN KINASES .7. THE MAPK SIGNALING CASCADE | 1995 | 2422 | 88 | 66% |
Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions | 2000 | 884 | 173 | 36% |
SPECIFICITY OF RECEPTOR TYROSINE KINASE SIGNALING - TRANSIENT VERSUS SUSTAINED EXTRACELLULAR SIGNAL-REGULATED KINASE ACTIVATION | 1995 | 3715 | 68 | 34% |
HOW MAP KINASES ARE REGULATED | 1995 | 1475 | 55 | 60% |
Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance | 2006 | 303 | 104 | 35% |
Raf kinases: Function, regulation and role in human cancer | 2007 | 79 | 187 | 49% |
Signal transduction through MAP kinase cascades | 1998 | 1170 | 787 | 19% |
MAP kinase pathways | 1999 | 619 | 198 | 34% |
THE MITOGEN-ACTIVATED PROTEIN-KINASE SIGNAL-TRANSDUCTION PATHWAY | 1993 | 1933 | 47 | 43% |
Raf: A strategic target for therapeutic development against cancer | 2005 | 156 | 205 | 43% |
Address terms |
Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | LEO JENKINS CANC | 11 | 29% | 2.0% | 32 |
2 | MED STRAHLENKUNDE ZELLFOR | 6 | 20% | 1.6% | 26 |
3 | MED MED CLIN IMMUNOL ALLERGY | 4 | 67% | 0.2% | 4 |
4 | ESCUELA QUIM FARM | 2 | 23% | 0.4% | 7 |
5 | 110 | 1 | 38% | 0.2% | 3 |
6 | 10833 LE CONTE AVE52175 CHS | 1 | 100% | 0.1% | 2 |
7 | MEMBER LEO JENKINS CANC | 1 | 100% | 0.1% | 2 |
8 | MED STRAHLENKUNDE ZELLFOR MSZ | 1 | 25% | 0.2% | 4 |
9 | CANC CAMPAIGN CELL MOL BIOL | 1 | 33% | 0.1% | 2 |
10 | ABL BASIC | 1 | 50% | 0.1% | 1 |
Related classes at same level (level 1) |
Rank | Relatedness score | Related classes |
---|---|---|
1 | 0.0000221082 | KSR1//PEA 15//IST ENDOCRINOL ONCOL SPERIMENTALE GAETANO SALVA |
2 | 0.0000123788 | BIOMARKERS BRANCH//CLONOGEN//COLORADO PARTY |
3 | 0.0000122724 | CYTOSTATIC FACTOR//MOS ONCOGENE//MPF |
4 | 0.0000116632 | RUFFLE//PROTEIN KINASE N//PC12 MUTANT CELLS |
5 | 0.0000114417 | MKP 1//MAP KINASE PHOSPHATASE//DUAL SPECIFICITY PHOSPHATASE |
6 | 0.0000105357 | S6K2//S6 KINASE//RIBOSOMAL S6 KINASE 2 S6K2 |
7 | 0.0000095854 | FARNESYLTHIOSALICYLIC ACID//SALIRASIB//ABT STRUKTURELLE BIOL |
8 | 0.0000087830 | V ERB B//V ERBB//ACUTE RETROVIRUS |
9 | 0.0000079652 | JNK//MKK4//JNK3 |
10 | 0.0000074643 | RLIP76//RALBP1//RAL |